Navigation Links
BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Date:9/19/2007

.biocryst.com or by dialing 1-800-860- 2442 (U.S.) or 1-412-858-4600 (international). No passcode is needed for the call.

BioCryst is also currently conducting a Phase II clinical trial studying an intravenous formulation of peramivir in hospitalized patients. That trial is designed to compare the efficacy and safety of intravenous peramivir to orally administered oseltamivir in patients who require hospitalization due to acute influenza.

BioCryst is developing peramivir injection for the treatment of acute influenza, including infection caused by highly virulent, life-threatening strains of influenza. In January, 2006 BioCryst received FDA Fast Track designation for the development of peramivir injection for this indication.

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 3, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst has retained all of its development and commercialization rights to peramivir worldwide except for in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. Peramivir injection has recei
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... on researching,developing, manufacturing and marketing biopharmaceutical products,primarily ... filed with the Chinese,State Food and Drug ... IU,dosage formulation of EPIAO for the treatment ...
... of Business ... Development Activities -, LA JOLLA, Calif., Sept. ... it will transition from a,discovery and development company to a development-only ... will,streamline operations through the shut down of its discovery operations,and seek ...
... Cells and Other ... Development Programs, ROCKVILLE, Md., ... immunotherapeutics to treat,autoimmune disorders, cancer and infectious diseases, today announced that,it ... led by,Nextech Venture, included additional new investors Arcus Ventures, Innovis,Investments and ...
Cached Biology Technology:3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
(Date:7/9/2014)... accrue. To completely and systematically archive this body ... researchers in the life sciences spend a quarter ... online survey of 70 people working in biology ... Information Technology FIT in Sankt Augustin. Many of ... or structured approach to data collection in their ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Traffic accidents involving wildlife are on the rise in Europe. ... be useful for increasing safety and preventing human and animal ... researchers have established at what time, on what day of ... roe deer are most likely to take place. Car ...
... that cancerous tumors grow collections of abnormal blood cells, the ... new evidence in an animal model suggests that blood vessels ... same purposeand could provide the key to a new way ... L. Makey, Edmund Chinchar, Carissa Howie, and Lucio Miele, all ...
... Animal sanctuaries can play an important role in rehabilitating goats ... scientists at Queen Mary, University of London. In ... moods in 18 goats, nine of which had endured poor ... shelter before arriving at a sanctuary. They created a spatial ...
Cached Biology News:Roe deer more likely to be run over at nightfall on a Sunday in April 2Drug reduces fat by blocking blood vessels 2Drug reduces fat by blocking blood vessels 3Rescue me: New study finds animals do recover from neglect 2
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
HSPBP1 Antibody...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: